The BC Cancer Agency’s Genito-Urinary tumour group and Radiotherapy Program approve and implement HDR brachytherapy “boost” (implanted radiation in addition to standard external beam radiation) as standard treatment for patients with both high-tier intermediate and high-risk prostate cancer, meaning this evolutionary treatment improvement will benefit patients who need it most. HDR brachytherapy boost can now be delivered to eligible prostate cancer patients, not as an experimental treatment, but as part of standard care. HDR brachytherapy was developed at the Sindi Ahluwalia Hawkins Centre for the Southern Interior by Dr. Ross Halperin, Dr. Juanita Crook, Dr. Francois Bachand, Dr. Rezwan Chowdhury and their colleagues.